TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3340
AB  - Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach
VL  - 38
IS  - 3
SP  - 323
EP  - 331
DO  - 10.2478/jomb-2018-0030
ER  - 

@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2019",
abstract = "Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach",
volume = "38",
number = "3",
pages = "323-331",
doi = "10.2478/jomb-2018-0030"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2019). Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 323-331.
https://doi.org/10.2478/jomb-2018-0030

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry. 2019;38(3):323-331.
doi:10.2478/jomb-2018-0030 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach" in Journal of Medical Biochemistry, 38, no. 3 (2019):323-331,
https://doi.org/10.2478/jomb-2018-0030 . .

TY  - JOUR
AU  - Miletić, Jadranka
AU  - Drakulić, Dunja
AU  - Pejić, Snežana
AU  - Petković, Marijana
AU  - Ilić, Tihomir V.
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Prostran, Milica
AU  - Stojanov, Marina
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3163
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3420
AB  - Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.
PB  - Taylor & Francis Ltd, Abingdon
T2  - International Journal of Neuroscience
T1  - Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease
VL  - 128
IS  - 7
SP  - 600
EP  - 607
DO  - 10.1080/00207454.2017.1403916
ER  - 

@article{
author = "Miletić, Jadranka and Drakulić, Dunja and Pejić, Snežana and Petković, Marijana and Ilić, Tihomir V. and Miljković, Milica and Stefanović, Aleksandra and Prostran, Milica and Stojanov, Marina",
year = "2018",
abstract = "Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "International Journal of Neuroscience",
title = "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease",
volume = "128",
number = "7",
pages = "600-607",
doi = "10.1080/00207454.2017.1403916"
}

Miletić, J., Drakulić, D., Pejić, S., Petković, M., Ilić, T. V., Miljković, M., Stefanović, A., Prostran, M.,& Stojanov, M.. (2018). Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience
Taylor & Francis Ltd, Abingdon., 128(7), 600-607.
https://doi.org/10.1080/00207454.2017.1403916

Miletić J, Drakulić D, Pejić S, Petković M, Ilić TV, Miljković M, Stefanović A, Prostran M, Stojanov M. Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience. 2018;128(7):600-607.
doi:10.1080/00207454.2017.1403916 .

Miletić, Jadranka, Drakulić, Dunja, Pejić, Snežana, Petković, Marijana, Ilić, Tihomir V., Miljković, Milica, Stefanović, Aleksandra, Prostran, Milica, Stojanov, Marina, "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease" in International Journal of Neuroscience, 128, no. 7 (2018):600-607,
https://doi.org/10.1080/00207454.2017.1403916 . .

TY  - JOUR
AU  - Miletić, Jadranka
AU  - Drakulić, Dunja
AU  - Pejić, Snežana
AU  - Petković, Marijana
AU  - Ilić, Tihomir V.
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Prostran, Milica
AU  - Stojanov, Marina
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3163
AB  - Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.
PB  - Taylor & Francis Ltd, Abingdon
T2  - International Journal of Neuroscience
T1  - Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease
VL  - 128
IS  - 7
SP  - 600
EP  - 607
DO  - 10.1080/00207454.2017.1403916
ER  - 

@article{
author = "Miletić, Jadranka and Drakulić, Dunja and Pejić, Snežana and Petković, Marijana and Ilić, Tihomir V. and Miljković, Milica and Stefanović, Aleksandra and Prostran, Milica and Stojanov, Marina",
year = "2018",
abstract = "Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "International Journal of Neuroscience",
title = "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease",
volume = "128",
number = "7",
pages = "600-607",
doi = "10.1080/00207454.2017.1403916"
}

Miletić, J., Drakulić, D., Pejić, S., Petković, M., Ilić, T. V., Miljković, M., Stefanović, A., Prostran, M.,& Stojanov, M.. (2018). Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience
Taylor & Francis Ltd, Abingdon., 128(7), 600-607.
https://doi.org/10.1080/00207454.2017.1403916

Miletić J, Drakulić D, Pejić S, Petković M, Ilić TV, Miljković M, Stefanović A, Prostran M, Stojanov M. Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience. 2018;128(7):600-607.
doi:10.1080/00207454.2017.1403916 .

Miletić, Jadranka, Drakulić, Dunja, Pejić, Snežana, Petković, Marijana, Ilić, Tihomir V., Miljković, Milica, Stefanović, Aleksandra, Prostran, Milica, Stojanov, Marina, "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease" in International Journal of Neuroscience, 128, no. 7 (2018):600-607,
https://doi.org/10.1080/00207454.2017.1403916 . .

TY  - JOUR
AU  - Ljubojević, Gordana
AU  - Miljković, Branislava
AU  - Bucma, Tatjana
AU  - Ćulafić, Milica
AU  - Prostran, Milica
AU  - Vezmar-Kovačević, Sandra
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2801
AB  - Background In the last 30 years, activities of hospital pharmacists have gone through significant changes. Pharmacists are increasingly involved in patient care. Objectives To explore drug-related and logistic problems, interventions, and their outcomes during routine everyday work of hospital pharmacists. Setting Institute for physical medicine and rehabilitation, Banja Luka, Bosnia and Herzegovina. Methods In the period of January 2013-October 2015 a prospective observational study was performed. Medical doctors, nurses, therapists, and patients addressed pharmacists, face-to-face or by telephone, with drug-related problems (DRPs) and/or logistic issues. Main outcome measure Type of DRP or logistic issue, intervention, outcome, initiator and time spent for solving the problem were documented for each consultation. Results Out of 1515 interventions, 48.8% were aimed at solving DRPs. The most common DRPs were the recommendation of a drug or dose and need for additional information about drugs. Drug price and supply were the most prevalent logistic issues. DRPs were more frequently initiated by medical doctors and required more time to solve the problem compared to logistic issues (Mann-Whitney U test, p  lt = 0.001, respectively). The acceptance rate of interventions to solve DRPs (83.7%) was lower compared to logistic issues (95.2%; p  lt = 0.001). Conclusions Hospital pharmacists were faced with an approximately equal number of DRPs and logistic issues during their routine everyday work. The overall acceptance rate of pharmacists' interventions was high, and the results of our study indicate that there is a need for more involvement of hospital pharmacists in Bosnia and Herzegovina in clinical activities. Impact on practice.
PB  - Springer, Dordrecht
T2  - International Journal of Clinical Pharmacy
T1  - Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina
VL  - 39
IS  - 4
SP  - 743
EP  - 749
DO  - 10.1007/s11096-017-0491-x
ER  - 

@article{
author = "Ljubojević, Gordana and Miljković, Branislava and Bucma, Tatjana and Ćulafić, Milica and Prostran, Milica and Vezmar-Kovačević, Sandra",
year = "2017",
abstract = "Background In the last 30 years, activities of hospital pharmacists have gone through significant changes. Pharmacists are increasingly involved in patient care. Objectives To explore drug-related and logistic problems, interventions, and their outcomes during routine everyday work of hospital pharmacists. Setting Institute for physical medicine and rehabilitation, Banja Luka, Bosnia and Herzegovina. Methods In the period of January 2013-October 2015 a prospective observational study was performed. Medical doctors, nurses, therapists, and patients addressed pharmacists, face-to-face or by telephone, with drug-related problems (DRPs) and/or logistic issues. Main outcome measure Type of DRP or logistic issue, intervention, outcome, initiator and time spent for solving the problem were documented for each consultation. Results Out of 1515 interventions, 48.8% were aimed at solving DRPs. The most common DRPs were the recommendation of a drug or dose and need for additional information about drugs. Drug price and supply were the most prevalent logistic issues. DRPs were more frequently initiated by medical doctors and required more time to solve the problem compared to logistic issues (Mann-Whitney U test, p  lt = 0.001, respectively). The acceptance rate of interventions to solve DRPs (83.7%) was lower compared to logistic issues (95.2%; p  lt = 0.001). Conclusions Hospital pharmacists were faced with an approximately equal number of DRPs and logistic issues during their routine everyday work. The overall acceptance rate of pharmacists' interventions was high, and the results of our study indicate that there is a need for more involvement of hospital pharmacists in Bosnia and Herzegovina in clinical activities. Impact on practice.",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina",
volume = "39",
number = "4",
pages = "743-749",
doi = "10.1007/s11096-017-0491-x"
}

Ljubojević, G., Miljković, B., Bucma, T., Ćulafić, M., Prostran, M.,& Vezmar-Kovačević, S.. (2017). Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 39(4), 743-749.
https://doi.org/10.1007/s11096-017-0491-x

Ljubojević G, Miljković B, Bucma T, Ćulafić M, Prostran M, Vezmar-Kovačević S. Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina. in International Journal of Clinical Pharmacy. 2017;39(4):743-749.
doi:10.1007/s11096-017-0491-x .

Ljubojević, Gordana, Miljković, Branislava, Bucma, Tatjana, Ćulafić, Milica, Prostran, Milica, Vezmar-Kovačević, Sandra, "Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina" in International Journal of Clinical Pharmacy, 39, no. 4 (2017):743-749,
https://doi.org/10.1007/s11096-017-0491-x . .

TY  - CONF
AU  - Golubović, Bojana
AU  - Drndarević, Aneta
AU  - Draganov, Ivana
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2720
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Potential drug-drug interactions in kidney transplant patients.
VL  - 36
IS  - 7
SP  - e96
EP  - e96
DO  - 10.1002/phar.1782
ER  - 

@conference{
author = "Golubović, Bojana and Drndarević, Aneta and Draganov, Ivana and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Prostran, Milica and Miljković, Branislava",
year = "2016",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Potential drug-drug interactions in kidney transplant patients.",
volume = "36",
number = "7",
pages = "e96-e96",
doi = "10.1002/phar.1782"
}

Golubović, B., Drndarević, A., Draganov, I., Radivojević, D., Vezmar-Kovačević, S., Vučićević, K., Prostran, M.,& Miljković, B.. (2016). Potential drug-drug interactions in kidney transplant patients.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 36(7), e96-e96.
https://doi.org/10.1002/phar.1782

Golubović B, Drndarević A, Draganov I, Radivojević D, Vezmar-Kovačević S, Vučićević K, Prostran M, Miljković B. Potential drug-drug interactions in kidney transplant patients.. in Pharmacotherapy. 2016;36(7):e96-e96.
doi:10.1002/phar.1782 .

Golubović, Bojana, Drndarević, Aneta, Draganov, Ivana, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Prostran, Milica, Miljković, Branislava, "Potential drug-drug interactions in kidney transplant patients." in Pharmacotherapy, 36, no. 7 (2016):e96-e96,
https://doi.org/10.1002/phar.1782 . .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Prostran, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Grabnar, Iztok
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2678
AB  - Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Medicinal Chemistry
T1  - Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients
VL  - 23
IS  - 19
SP  - 1998
EP  - 2011
DO  - 10.2174/0929867323666151221150214
ER  - 

@article{
author = "Golubović, Bojana and Prostran, Milica and Miljković, Branislava and Vučićević, Katarina and Radivojević, Dragana and Grabnar, Iztok",
year = "2016",
abstract = "Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Medicinal Chemistry",
title = "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients",
volume = "23",
number = "19",
pages = "1998-2011",
doi = "10.2174/0929867323666151221150214"
}

Golubović, B., Prostran, M., Miljković, B., Vučićević, K., Radivojević, D.,& Grabnar, I.. (2016). Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 23(19), 1998-2011.
https://doi.org/10.2174/0929867323666151221150214

Golubović B, Prostran M, Miljković B, Vučićević K, Radivojević D, Grabnar I. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry. 2016;23(19):1998-2011.
doi:10.2174/0929867323666151221150214 .

Golubović, Bojana, Prostran, Milica, Miljković, Branislava, Vučićević, Katarina, Radivojević, Dragana, Grabnar, Iztok, "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients" in Current Medicinal Chemistry, 23, no. 19 (2016):1998-2011,
https://doi.org/10.2174/0929867323666151221150214 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Prostran, Milica
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2553
AB  - Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese children and adolescent patients, requiring changes in usual dosage regimen.
AB  - Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja.
PB  - Most Art doo, Beograd
T2  - MD - Medical data
T1  - Pharmacokinetic considerations in drug dosing to pediatric obese patients
T1  - Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima
VL  - 8
IS  - 3
SP  - 149
EP  - 153
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2553
ER  - 

@article{
author = "Vučićević, Katarina and Miljković, Branislava and Prostran, Milica",
year = "2016",
abstract = "Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese children and adolescent patients, requiring changes in usual dosage regimen., Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja.",
publisher = "Most Art doo, Beograd",
journal = "MD - Medical data",
title = "Pharmacokinetic considerations in drug dosing to pediatric obese patients, Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima",
volume = "8",
number = "3",
pages = "149-153",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2553"
}

Vučićević, K., Miljković, B.,& Prostran, M.. (2016). Pharmacokinetic considerations in drug dosing to pediatric obese patients. in MD - Medical data
Most Art doo, Beograd., 8(3), 149-153.
https://hdl.handle.net/21.15107/rcub_farfar_2553

Vučićević K, Miljković B, Prostran M. Pharmacokinetic considerations in drug dosing to pediatric obese patients. in MD - Medical data. 2016;8(3):149-153.
https://hdl.handle.net/21.15107/rcub_farfar_2553 .

Vučićević, Katarina, Miljković, Branislava, Prostran, Milica, "Pharmacokinetic considerations in drug dosing to pediatric obese patients" in MD - Medical data, 8, no. 3 (2016):149-153,
https://hdl.handle.net/21.15107/rcub_farfar_2553 .

TY  - JOUR
AU  - Ilić, V
AU  - Bogićević, Dragana
AU  - Miljković, Branislava
AU  - Ješić, M
AU  - Kovačević, M
AU  - Prostran, Milica
AU  - Vezmar-Kovačević, Sandra
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2767
AB  - Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.
PB  - John Libbey Eurotext
T2  - Epileptic Disorders
T1  - Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy
VL  - 18
IS  - 2
SP  - 181
EP  - 186
DO  - 10.1684/epd.2016.0821
ER  - 

@article{
author = "Ilić, V and Bogićević, Dragana and Miljković, Branislava and Ješić, M and Kovačević, M and Prostran, Milica and Vezmar-Kovačević, Sandra",
year = "2016",
abstract = "Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.",
publisher = "John Libbey Eurotext",
journal = "Epileptic Disorders",
title = "Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy",
volume = "18",
number = "2",
pages = "181-186",
doi = "10.1684/epd.2016.0821"
}

Ilić, V., Bogićević, D., Miljković, B., Ješić, M., Kovačević, M., Prostran, M.,& Vezmar-Kovačević, S.. (2016). Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. in Epileptic Disorders
John Libbey Eurotext., 18(2), 181-186.
https://doi.org/10.1684/epd.2016.0821

Ilić V, Bogićević D, Miljković B, Ješić M, Kovačević M, Prostran M, Vezmar-Kovačević S. Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. in Epileptic Disorders. 2016;18(2):181-186.
doi:10.1684/epd.2016.0821 .

Ilić, V, Bogićević, Dragana, Miljković, Branislava, Ješić, M, Kovačević, M, Prostran, Milica, Vezmar-Kovačević, Sandra, "Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy" in Epileptic Disorders, 18, no. 2 (2016):181-186,
https://doi.org/10.1684/epd.2016.0821 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2453
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Prediction of topiramate serum levels according to variability factors using artificial neural networks.
VL  - 35
IS  - 5
SP  - e75
EP  - e76
DO  - 10.1002/phar.1606
ER  - 

@conference{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Prediction of topiramate serum levels according to variability factors using artificial neural networks.",
volume = "35",
number = "5",
pages = "e75-e76",
doi = "10.1002/phar.1606"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Prediction of topiramate serum levels according to variability factors using artificial neural networks.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 35(5), e75-e76.
https://doi.org/10.1002/phar.1606

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Prediction of topiramate serum levels according to variability factors using artificial neural networks.. in Pharmacotherapy. 2015;35(5):e75-e76.
doi:10.1002/phar.1606 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Prediction of topiramate serum levels according to variability factors using artificial neural networks." in Pharmacotherapy, 35, no. 5 (2015):e75-e76,
https://doi.org/10.1002/phar.1606 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Jovanović, Marija
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Prostran, Milica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2408
AB  - The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients
VL  - 71
IS  - 2
SP  - 183
EP  - 190
DO  - 10.1007/s00228-014-1778-7
ER  - 

@article{
author = "Vučićević, Katarina and Jovanović, Marija and Golubović, Bojana and Vezmar-Kovačević, Sandra and Miljković, Branislava and Martinović, Žarko J. and Prostran, Milica",
year = "2015",
abstract = "The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients",
volume = "71",
number = "2",
pages = "183-190",
doi = "10.1007/s00228-014-1778-7"
}

Vučićević, K., Jovanović, M., Golubović, B., Vezmar-Kovačević, S., Miljković, B., Martinović, Ž. J.,& Prostran, M.. (2015). Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 71(2), 183-190.
https://doi.org/10.1007/s00228-014-1778-7

Vučićević K, Jovanović M, Golubović B, Vezmar-Kovačević S, Miljković B, Martinović ŽJ, Prostran M. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology. 2015;71(2):183-190.
doi:10.1007/s00228-014-1778-7 .

Vučićević, Katarina, Jovanović, Marija, Golubović, Bojana, Vezmar-Kovačević, Sandra, Miljković, Branislava, Martinović, Žarko J., Prostran, Milica, "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients" in European Journal of Clinical Pharmacology, 71, no. 2 (2015):183-190,
https://doi.org/10.1007/s00228-014-1778-7 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2366
AB  - Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.
PB  - Canadian Soc Pharmaceutical Sciences, Edmonton
T2  - Journal of Pharmacy and Pharmaceutical Sciences
T1  - Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy
VL  - 18
IS  - 5
SP  - 856
EP  - 862
DO  - 10.18433/J33031
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
abstract = "Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.",
publisher = "Canadian Soc Pharmaceutical Sciences, Edmonton",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
title = "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy",
volume = "18",
number = "5",
pages = "856-862",
doi = "10.18433/J33031"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences
Canadian Soc Pharmaceutical Sciences, Edmonton., 18(5), 856-862.
https://doi.org/10.18433/J33031

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences. 2015;18(5):856-862.
doi:10.18433/J33031 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy" in Journal of Pharmacy and Pharmaceutical Sciences, 18, no. 5 (2015):856-862,
https://doi.org/10.18433/J33031 . .

TY  - JOUR
AU  - Vezmar-Kovačević, Sandra
AU  - Simisić, Mika
AU  - Stojkov-Rudinski, Svetlana
AU  - Ćulafić, Milica
AU  - Vučićević, Katarina
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2227
AB  - Objectives: The aim of the study was to determine the rate of Potentially Inappropriate Medicines (PIM) and Potential Prescription Omissions (PPO) according to Screening Tool of Older Person's potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment (STOPP/START) criteria. Study Design: A cross-sectional survey in community pharmacy. Method: A prospective cross-sectional study was performed, during March-May 2012, in five community pharmacies. Patients aged >= 65 years, who collected one or more prescribed medications, were asked to participate in the study, and an interview was scheduled. Patients were asked to provide their complete medical and biochemical record from their general practitioner. Results: 509 patients, mean age 74.8 +/- 6.5 years, 57.4% female, participated in the study. 164 PIM were identified in 139 patients (27.3%). The most common were: long-term use of long-acting benzodiazepines (20.7%), use of non-steroidal antiinflammatory drugs (NSAID) in patients with moderate-severe hypertension (20.1%), use of theophylline as monotherapy for chronic obstructive pulmonary disease (COPD, 15.9%) and use of aspirin without appropriate indication (15.2%). Patients with more than four prescpritions had a higher risk for PIM (OR 2.85, 95% CI 1.97-4.14, p lt 0.001). There were 439 PPO, identified in 257, (50.5%) patients. Predictors for PPO were older age, presence of diabetes, myocardial infarction, osteoporosis, stroke, COPD and/or angina pectoris. Conclusion: STOPP/START criteria may be useful in identifying inappropriate prescribing and improving the current prescribing practices. Pharmacists should focus more on patients with more than four medications and/or patients with gout or pain accompanied with arterial hypertension because those patient may be at higher risk of PIM. Additionlly, patients older than 74 years with diabetes, osteoporosis, myocardial infarction, stroke, angina pectoris and/or COPD may have an increased risk of PPO.
PB  - Public Library Science, San Francisco
T2  - PLoS One
T1  - Potentially Inappropriate Prescribing in Older Primary Care Patients
VL  - 9
IS  - 4
DO  - 10.1371/journal.pone.0095536
ER  - 

@article{
author = "Vezmar-Kovačević, Sandra and Simisić, Mika and Stojkov-Rudinski, Svetlana and Ćulafić, Milica and Vučićević, Katarina and Prostran, Milica and Miljković, Branislava",
year = "2014",
abstract = "Objectives: The aim of the study was to determine the rate of Potentially Inappropriate Medicines (PIM) and Potential Prescription Omissions (PPO) according to Screening Tool of Older Person's potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment (STOPP/START) criteria. Study Design: A cross-sectional survey in community pharmacy. Method: A prospective cross-sectional study was performed, during March-May 2012, in five community pharmacies. Patients aged >= 65 years, who collected one or more prescribed medications, were asked to participate in the study, and an interview was scheduled. Patients were asked to provide their complete medical and biochemical record from their general practitioner. Results: 509 patients, mean age 74.8 +/- 6.5 years, 57.4% female, participated in the study. 164 PIM were identified in 139 patients (27.3%). The most common were: long-term use of long-acting benzodiazepines (20.7%), use of non-steroidal antiinflammatory drugs (NSAID) in patients with moderate-severe hypertension (20.1%), use of theophylline as monotherapy for chronic obstructive pulmonary disease (COPD, 15.9%) and use of aspirin without appropriate indication (15.2%). Patients with more than four prescpritions had a higher risk for PIM (OR 2.85, 95% CI 1.97-4.14, p lt 0.001). There were 439 PPO, identified in 257, (50.5%) patients. Predictors for PPO were older age, presence of diabetes, myocardial infarction, osteoporosis, stroke, COPD and/or angina pectoris. Conclusion: STOPP/START criteria may be useful in identifying inappropriate prescribing and improving the current prescribing practices. Pharmacists should focus more on patients with more than four medications and/or patients with gout or pain accompanied with arterial hypertension because those patient may be at higher risk of PIM. Additionlly, patients older than 74 years with diabetes, osteoporosis, myocardial infarction, stroke, angina pectoris and/or COPD may have an increased risk of PPO.",
publisher = "Public Library Science, San Francisco",
journal = "PLoS One",
title = "Potentially Inappropriate Prescribing in Older Primary Care Patients",
volume = "9",
number = "4",
doi = "10.1371/journal.pone.0095536"
}

Vezmar-Kovačević, S., Simisić, M., Stojkov-Rudinski, S., Ćulafić, M., Vučićević, K., Prostran, M.,& Miljković, B.. (2014). Potentially Inappropriate Prescribing in Older Primary Care Patients. in PLoS One
Public Library Science, San Francisco., 9(4).
https://doi.org/10.1371/journal.pone.0095536

Vezmar-Kovačević S, Simisić M, Stojkov-Rudinski S, Ćulafić M, Vučićević K, Prostran M, Miljković B. Potentially Inappropriate Prescribing in Older Primary Care Patients. in PLoS One. 2014;9(4).
doi:10.1371/journal.pone.0095536 .

Vezmar-Kovačević, Sandra, Simisić, Mika, Stojkov-Rudinski, Svetlana, Ćulafić, Milica, Vučićević, Katarina, Prostran, Milica, Miljković, Branislava, "Potentially Inappropriate Prescribing in Older Primary Care Patients" in PLoS One, 9, no. 4 (2014),
https://doi.org/10.1371/journal.pone.0095536 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2198
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Influence of topiramate therapy duration on serum bicarbonate levels in adults
VL  - 34
IS  - 6
SP  - e110
EP  - e110
DO  - 10.1002/phar.1449
ER  - 

@conference{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Influence of topiramate therapy duration on serum bicarbonate levels in adults",
volume = "34",
number = "6",
pages = "e110-e110",
doi = "10.1002/phar.1449"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Influence of topiramate therapy duration on serum bicarbonate levels in adults. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 34(6), e110-e110.
https://doi.org/10.1002/phar.1449

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Influence of topiramate therapy duration on serum bicarbonate levels in adults. in Pharmacotherapy. 2014;34(6):e110-e110.
doi:10.1002/phar.1449 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Influence of topiramate therapy duration on serum bicarbonate levels in adults" in Pharmacotherapy, 34, no. 6 (2014):e110-e110,
https://doi.org/10.1002/phar.1449 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2117
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis
VL  - 24
IS  - Supplement 2
SP  - S645
EP  - S645
DO  - 10.1016/S0924-977X(14)71037-5
ER  - 

@conference{
author = "Jovanović, Marija and Vučićević, Katarina and Golubović, Bojana and Vezmar-Kovačević, Sandra and Prostran, Milica and Martinović, Žarko J. and Miljković, Branislava",
year = "2014",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis",
volume = "24",
number = "Supplement 2",
pages = "S645-S645",
doi = "10.1016/S0924-977X(14)71037-5"
}

Jovanović, M., Vučićević, K., Golubović, B., Vezmar-Kovačević, S., Prostran, M., Martinović, Ž. J.,& Miljković, B.. (2014). No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 24(Supplement 2), S645-S645.
https://doi.org/10.1016/S0924-977X(14)71037-5

Jovanović M, Vučićević K, Golubović B, Vezmar-Kovačević S, Prostran M, Martinović ŽJ, Miljković B. No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis. in European Neuropsychopharmacology. 2014;24(Supplement 2):S645-S645.
doi:10.1016/S0924-977X(14)71037-5 .

Jovanović, Marija, Vučićević, Katarina, Golubović, Bojana, Vezmar-Kovačević, Sandra, Prostran, Milica, Martinović, Žarko J., Miljković, Branislava, "No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis" in European Neuropsychopharmacology, 24, no. Supplement 2 (2014):S645-S645,
https://doi.org/10.1016/S0924-977X(14)71037-5 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2091
AB  - Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Annals of Pharmacotherapy
T1  - Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients
VL  - 48
IS  - 8
SP  - 992
EP  - 997
DO  - 10.1177/1060028014534397
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
abstract = "Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Annals of Pharmacotherapy",
title = "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients",
volume = "48",
number = "8",
pages = "992-997",
doi = "10.1177/1060028014534397"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy
Sage Publications Inc, Thousand Oaks., 48(8), 992-997.
https://doi.org/10.1177/1060028014534397

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy. 2014;48(8):992-997.
doi:10.1177/1060028014534397 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients" in Annals of Pharmacotherapy, 48, no. 8 (2014):992-997,
https://doi.org/10.1177/1060028014534397 . .

TY  - CONF
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2199
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients
VL  - 34
IS  - 6
SP  - e114
EP  - e114
DO  - 10.1002/phar.1449
ER  - 

@conference{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients",
volume = "34",
number = "6",
pages = "e114-e114",
doi = "10.1002/phar.1449"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2014). Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 34(6), e114-e114.
https://doi.org/10.1002/phar.1449

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients. in Pharmacotherapy. 2014;34(6):e114-e114.
doi:10.1002/phar.1449 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients" in Pharmacotherapy, 34, no. 6 (2014):e114-e114,
https://doi.org/10.1002/phar.1449 . .

TY  - JOUR
AU  - Brzaković, Branka
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Pokrajac, Milena
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2183
AB  - The purpose of the study was to examine and describe adjunctive lamotrigine (LTG) pharmacokinetics in paediatric and young adult patients using a nonlinear mixed effects modelling (NONMEM) approach. The study included 53 patients (age range 3-35 years) who were concomitantly treated with carbamazepine (CBZ) and/or valproic acid (VPA). A total of 70 blood samples corresponding to trough levels were available for analysis. Data were modelled, and the final model was evaluated using NONMEM and auxiliary software tools. The final LTG population model included the effects of concomitant drugs and patient's weight (WT) which stratified the population into three groups: a parts per thousand currency sign25 kg, > 25 to  lt  60 kg and a parts per thousand yen60 kg. Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing a parts per thousand currency sign25 kg, > 25 to  lt  60 kg or a parts per thousand yen60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively. If a patient was concomitantly treated with CBZ + VPA, the CL/F decreased on average by 69.5 % relative to LTG + CBZ co-therapy. VPA was found to decrease the LTG CL/F by 87.6 % compared to co-therapy with only CBZ. The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach
VL  - 70
IS  - 2
SP  - 179
EP  - 185
DO  - 10.1007/s00228-013-1606-5
ER  - 

@article{
author = "Brzaković, Branka and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava and Prostran, Milica and Martinović, Žarko J. and Pokrajac, Milena",
year = "2014",
abstract = "The purpose of the study was to examine and describe adjunctive lamotrigine (LTG) pharmacokinetics in paediatric and young adult patients using a nonlinear mixed effects modelling (NONMEM) approach. The study included 53 patients (age range 3-35 years) who were concomitantly treated with carbamazepine (CBZ) and/or valproic acid (VPA). A total of 70 blood samples corresponding to trough levels were available for analysis. Data were modelled, and the final model was evaluated using NONMEM and auxiliary software tools. The final LTG population model included the effects of concomitant drugs and patient's weight (WT) which stratified the population into three groups: a parts per thousand currency sign25 kg, > 25 to  lt  60 kg and a parts per thousand yen60 kg. Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing a parts per thousand currency sign25 kg, > 25 to  lt  60 kg or a parts per thousand yen60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively. If a patient was concomitantly treated with CBZ + VPA, the CL/F decreased on average by 69.5 % relative to LTG + CBZ co-therapy. VPA was found to decrease the LTG CL/F by 87.6 % compared to co-therapy with only CBZ. The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach",
volume = "70",
number = "2",
pages = "179-185",
doi = "10.1007/s00228-013-1606-5"
}

Brzaković, B., Vučićević, K., Vezmar-Kovačević, S., Miljković, B., Prostran, M., Martinović, Ž. J.,& Pokrajac, M.. (2014). Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 70(2), 179-185.
https://doi.org/10.1007/s00228-013-1606-5

Brzaković B, Vučićević K, Vezmar-Kovačević S, Miljković B, Prostran M, Martinović ŽJ, Pokrajac M. Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. in European Journal of Clinical Pharmacology. 2014;70(2):179-185.
doi:10.1007/s00228-013-1606-5 .

Brzaković, Branka, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, Prostran, Milica, Martinović, Žarko J., Pokrajac, Milena, "Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach" in European Journal of Clinical Pharmacology, 70, no. 2 (2014):179-185,
https://doi.org/10.1007/s00228-013-1606-5 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Rakonjac, Zorica
AU  - Miljković, Branislava
AU  - Janković, Borisav
AU  - Prostran, Milica
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2178
AB  - The purpose of the study was to compare peak (C-peak) and trough (C-trough) amikacin levels after twice-daily (TD) or once-daily dosing (OD) in full-term neonates. Additionally, the study aimed to address amikacin pharmacokinetics and its variability. Data included 31 patients born on term. Amikacin daily dose was 15 or 20 mg/kg depending on the neonate's age. Patients randomly received amikacin every 12 or 24 h. In all patients corresponding C-peak and C-trough were taken. Volume of distribution (Vd), clearance (CL) and half-life (t(1/2)) were calculated. Mean C-peak of 21.79 mu g/ml in the TD group was statistically different from C-peak of 36.39 mu g/ml in the OD group. Average C-trough in TD (5.67 mu g/ml) was statistically different from the corresponding 3.99 mu g/ml in the OD group. Mean amikacin Vd, CL, and tin were 0.78 +/- 0.38 l/kg, 86.99 +/- 48.22 ml/h.kg, and 6.81 +/- 2.51 h, respectively. High interindividual pharmacokinetic variability was observed. Further analysis showed that neonatal age contributed to the pharmacokinetic parameters' values. Statistically significant difference in CL and tin was observed between patients age  lt = 2 and > 2 days on therapy initiation. As expected, amikacin given OD achieved higher C-peak and lower C-trough than TD. Based on the results, observed variability in amikacin pharmacokinetics was possibly due to the renal maturation process.
PB  - Japanese Pharmacological Soc, Kyoto
T2  - Journal of Pharmacological Sciences
T1  - Pharmacokinetic Variability of Amikacin After Once-Daily and Twice-Daily Dosing Regimen in Full-Term Neonates
VL  - 124
IS  - 2
SP  - 138
EP  - 143
DO  - 10.1254/jphs.13126FP
ER  - 

@article{
author = "Vučićević, Katarina and Rakonjac, Zorica and Miljković, Branislava and Janković, Borisav and Prostran, Milica",
year = "2014",
abstract = "The purpose of the study was to compare peak (C-peak) and trough (C-trough) amikacin levels after twice-daily (TD) or once-daily dosing (OD) in full-term neonates. Additionally, the study aimed to address amikacin pharmacokinetics and its variability. Data included 31 patients born on term. Amikacin daily dose was 15 or 20 mg/kg depending on the neonate's age. Patients randomly received amikacin every 12 or 24 h. In all patients corresponding C-peak and C-trough were taken. Volume of distribution (Vd), clearance (CL) and half-life (t(1/2)) were calculated. Mean C-peak of 21.79 mu g/ml in the TD group was statistically different from C-peak of 36.39 mu g/ml in the OD group. Average C-trough in TD (5.67 mu g/ml) was statistically different from the corresponding 3.99 mu g/ml in the OD group. Mean amikacin Vd, CL, and tin were 0.78 +/- 0.38 l/kg, 86.99 +/- 48.22 ml/h.kg, and 6.81 +/- 2.51 h, respectively. High interindividual pharmacokinetic variability was observed. Further analysis showed that neonatal age contributed to the pharmacokinetic parameters' values. Statistically significant difference in CL and tin was observed between patients age  lt = 2 and > 2 days on therapy initiation. As expected, amikacin given OD achieved higher C-peak and lower C-trough than TD. Based on the results, observed variability in amikacin pharmacokinetics was possibly due to the renal maturation process.",
publisher = "Japanese Pharmacological Soc, Kyoto",
journal = "Journal of Pharmacological Sciences",
title = "Pharmacokinetic Variability of Amikacin After Once-Daily and Twice-Daily Dosing Regimen in Full-Term Neonates",
volume = "124",
number = "2",
pages = "138-143",
doi = "10.1254/jphs.13126FP"
}

Vučićević, K., Rakonjac, Z., Miljković, B., Janković, B.,& Prostran, M.. (2014). Pharmacokinetic Variability of Amikacin After Once-Daily and Twice-Daily Dosing Regimen in Full-Term Neonates. in Journal of Pharmacological Sciences
Japanese Pharmacological Soc, Kyoto., 124(2), 138-143.
https://doi.org/10.1254/jphs.13126FP

Vučićević K, Rakonjac Z, Miljković B, Janković B, Prostran M. Pharmacokinetic Variability of Amikacin After Once-Daily and Twice-Daily Dosing Regimen in Full-Term Neonates. in Journal of Pharmacological Sciences. 2014;124(2):138-143.
doi:10.1254/jphs.13126FP .

Vučićević, Katarina, Rakonjac, Zorica, Miljković, Branislava, Janković, Borisav, Prostran, Milica, "Pharmacokinetic Variability of Amikacin After Once-Daily and Twice-Daily Dosing Regimen in Full-Term Neonates" in Journal of Pharmacological Sciences, 124, no. 2 (2014):138-143,
https://doi.org/10.1254/jphs.13126FP . .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2174
AB  - Data from routine therapeutic drug monitoring of 105 adult kidney transplant recipients were used for population pharmacokinetic analysis which was performed using a non-linear mixed-effects modeling. The effect of demographic and clinical factors on tacrolimus clearance was evaluated. Following the initiation of treatment with tacrolimus, the results of our study indicate a decrease of the drug clearance on day 15, 1 and 6 months after transplantation for 4.4%, 6.3% and 10.92%, respectively. Our model suggests a negative correlation between tacrolimus clearance and haematocrit. According to final model, clearance decreases with increasing of aspartate aminotransferase. Our results demonstrated that CL/F increases with patients' weight. This study reveals incensement for 10.4% in tacrolimus clearance with alteration of patients' minimal measured total protein levels to upper normal range. The findings of this study explore various factors of tacrolimus pharmacokinetic variability and point out a relationship between tacrolimus clearance and total plasma protein. Developed model demonstrates the feasibility of estimation of individual tacrolimus clearance and may allow rational individualization of tacrolimus dosing in kidney transplant patients.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach
VL  - 52
SP  - 34
EP  - 40
DO  - 10.1016/j.ejps.2013.10.008
ER  - 

@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2014",
abstract = "Data from routine therapeutic drug monitoring of 105 adult kidney transplant recipients were used for population pharmacokinetic analysis which was performed using a non-linear mixed-effects modeling. The effect of demographic and clinical factors on tacrolimus clearance was evaluated. Following the initiation of treatment with tacrolimus, the results of our study indicate a decrease of the drug clearance on day 15, 1 and 6 months after transplantation for 4.4%, 6.3% and 10.92%, respectively. Our model suggests a negative correlation between tacrolimus clearance and haematocrit. According to final model, clearance decreases with increasing of aspartate aminotransferase. Our results demonstrated that CL/F increases with patients' weight. This study reveals incensement for 10.4% in tacrolimus clearance with alteration of patients' minimal measured total protein levels to upper normal range. The findings of this study explore various factors of tacrolimus pharmacokinetic variability and point out a relationship between tacrolimus clearance and total plasma protein. Developed model demonstrates the feasibility of estimation of individual tacrolimus clearance and may allow rational individualization of tacrolimus dosing in kidney transplant patients.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach",
volume = "52",
pages = "34-40",
doi = "10.1016/j.ejps.2013.10.008"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2014). Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 52, 34-40.
https://doi.org/10.1016/j.ejps.2013.10.008

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. in European Journal of Pharmaceutical Sciences. 2014;52:34-40.
doi:10.1016/j.ejps.2013.10.008 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach" in European Journal of Pharmaceutical Sciences, 52 (2014):34-40,
https://doi.org/10.1016/j.ejps.2013.10.008 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Rakonjac, Zorica
AU  - Janković, Borisav Z.
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Prostran, Milica
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2089
AB  - Gentamicin is readily used for suspected or proven sepsis in neonates, yet it shows considerable inter-individual pharmacokinetic variability, which limits achievements of therapeutic levels. Hence, the aim of this study was to compare peak and trough gentamicin concentrations according to dosing regimen, to evaluate pharmacokinetic parameters, and to consider adjustments of dosing regimen. Babies with infection were treated with 1 h infusion, and daily dose of 5 or 7.5 mg/kg depending on the age. Patients were randomized into two groups: I - dosing interval 12 h (n=8), II - 24 h (n=11). Two steady-state blood samples were obtained. Pharmacokinetic parameters were calculated using one-compartment model. The results showed a difference (p  lt  0.05) in peak gentamicin concentrations between the groups, and tendency of lower trough levels in the group II. Calculated pharmacokinetic parameters included the volume of distribution (Vd) 0.52 +/- 0.47 l/kg, clearance (CL) 0.055 +/- 0.036 l/hkg and a half-life (t(1/2)) of 6.89 +/- 3.21 h. Based on the method for dosing regimen adjustments, there was a need to extend dosing interval to 36 h in 6 patients.
PB  - De Gruyter Open Ltd, Warsaw
T2  - Central European Journal of Medicine
T1  - Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates
VL  - 9
IS  - 3
SP  - 485
EP  - 490
DO  - 10.2478/s11536-013-0298-7
ER  - 

@article{
author = "Vučićević, Katarina and Rakonjac, Zorica and Janković, Borisav Z. and Vezmar-Kovačević, Sandra and Miljković, Branislava and Prostran, Milica",
year = "2014",
abstract = "Gentamicin is readily used for suspected or proven sepsis in neonates, yet it shows considerable inter-individual pharmacokinetic variability, which limits achievements of therapeutic levels. Hence, the aim of this study was to compare peak and trough gentamicin concentrations according to dosing regimen, to evaluate pharmacokinetic parameters, and to consider adjustments of dosing regimen. Babies with infection were treated with 1 h infusion, and daily dose of 5 or 7.5 mg/kg depending on the age. Patients were randomized into two groups: I - dosing interval 12 h (n=8), II - 24 h (n=11). Two steady-state blood samples were obtained. Pharmacokinetic parameters were calculated using one-compartment model. The results showed a difference (p  lt  0.05) in peak gentamicin concentrations between the groups, and tendency of lower trough levels in the group II. Calculated pharmacokinetic parameters included the volume of distribution (Vd) 0.52 +/- 0.47 l/kg, clearance (CL) 0.055 +/- 0.036 l/hkg and a half-life (t(1/2)) of 6.89 +/- 3.21 h. Based on the method for dosing regimen adjustments, there was a need to extend dosing interval to 36 h in 6 patients.",
publisher = "De Gruyter Open Ltd, Warsaw",
journal = "Central European Journal of Medicine",
title = "Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates",
volume = "9",
number = "3",
pages = "485-490",
doi = "10.2478/s11536-013-0298-7"
}

Vučićević, K., Rakonjac, Z., Janković, B. Z., Vezmar-Kovačević, S., Miljković, B.,& Prostran, M.. (2014). Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates. in Central European Journal of Medicine
De Gruyter Open Ltd, Warsaw., 9(3), 485-490.
https://doi.org/10.2478/s11536-013-0298-7

Vučićević K, Rakonjac Z, Janković BZ, Vezmar-Kovačević S, Miljković B, Prostran M. Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates. in Central European Journal of Medicine. 2014;9(3):485-490.
doi:10.2478/s11536-013-0298-7 .

Vučićević, Katarina, Rakonjac, Zorica, Janković, Borisav Z., Vezmar-Kovačević, Sandra, Miljković, Branislava, Prostran, Milica, "Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates" in Central European Journal of Medicine, 9, no. 3 (2014):485-490,
https://doi.org/10.2478/s11536-013-0298-7 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1844
AB  - The objective of the study was to develop population pharmacokinetic model of topiramate (TPM) using nonlinear mixed effects modelling approach. Data were collected from 78 adult epileptic patients on mono- or co-therapy of TPM and other antiepileptic drugs, such as carbamazepine (CBZ), valproic acid, lamotrigine, levetiracetam, phenobarbital and pregabalin. Steady-state TPM concentrations were determined in blood samples by high performance liquid chromatography with fluorescence detection. A one-compartment model with first order absorption and elimination was used to fit the concentration-time TPM data. Volume of distribution of TPM was estimated at 0.575 l/kg. The influence of demographic, biochemical parameters and therapy characteristics of the patients on oral clearance (CL/F) was evaluated. Daily carbamazepine dose (DCBZ) and renal function estimated by Modification of diet in renal disease (MDRD) formula significantly (p  lt  0.001) influenced CL/F and were included in the final model: CL/F . (l/h) = 1.53(1/h) . [1 + 0.476 . DCBZ(mg/day)/1000(mg/day)] . EXP[0.00476 . [MDRD(ml/min) -95.72(ml/ mm)]]. Increase of CL/F with DCBZ and MDRD was best described by linear and exponential models. Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ. Evaluation by bootstrapping showed that the final model was stable. The predictive performance was evaluated by adequate plots and indicated satisfactory precision. This model allows individualisation of TPM dosing in routine patient care, especially useful for patients on different CBZ dosing regimen.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling
VL  - 50
IS  - 3-4
SP  - 282
EP  - 289
DO  - 10.1016/j.ejps.2013.07.008
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Vučićević, Katarina and Miljković, Branislava",
year = "2013",
abstract = "The objective of the study was to develop population pharmacokinetic model of topiramate (TPM) using nonlinear mixed effects modelling approach. Data were collected from 78 adult epileptic patients on mono- or co-therapy of TPM and other antiepileptic drugs, such as carbamazepine (CBZ), valproic acid, lamotrigine, levetiracetam, phenobarbital and pregabalin. Steady-state TPM concentrations were determined in blood samples by high performance liquid chromatography with fluorescence detection. A one-compartment model with first order absorption and elimination was used to fit the concentration-time TPM data. Volume of distribution of TPM was estimated at 0.575 l/kg. The influence of demographic, biochemical parameters and therapy characteristics of the patients on oral clearance (CL/F) was evaluated. Daily carbamazepine dose (DCBZ) and renal function estimated by Modification of diet in renal disease (MDRD) formula significantly (p  lt  0.001) influenced CL/F and were included in the final model: CL/F . (l/h) = 1.53(1/h) . [1 + 0.476 . DCBZ(mg/day)/1000(mg/day)] . EXP[0.00476 . [MDRD(ml/min) -95.72(ml/ mm)]]. Increase of CL/F with DCBZ and MDRD was best described by linear and exponential models. Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ. Evaluation by bootstrapping showed that the final model was stable. The predictive performance was evaluated by adequate plots and indicated satisfactory precision. This model allows individualisation of TPM dosing in routine patient care, especially useful for patients on different CBZ dosing regimen.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling",
volume = "50",
number = "3-4",
pages = "282-289",
doi = "10.1016/j.ejps.2013.07.008"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Vučićević, K.,& Miljković, B.. (2013). Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 50(3-4), 282-289.
https://doi.org/10.1016/j.ejps.2013.07.008

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Vučićević K, Miljković B. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. in European Journal of Pharmaceutical Sciences. 2013;50(3-4):282-289.
doi:10.1016/j.ejps.2013.07.008 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Vučićević, Katarina, Miljković, Branislava, "Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling" in European Journal of Pharmaceutical Sciences, 50, no. 3-4 (2013):282-289,
https://doi.org/10.1016/j.ejps.2013.07.008 . .

TY  - JOUR
AU  - Antunović, Tanja
AU  - Stefanović, Aleksandra
AU  - Ratković, Marina
AU  - Gledović, Branka
AU  - Gligorović-Barhanović, Najdana
AU  - Bozović, Dragica
AU  - Ivanišević, Jasmina
AU  - Prostran, Milica
AU  - Stojanov, Marina
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1974
AB  - We investigated the role of serum uric acid (sUA) and superoxide dismutase (SOD) as predictive factors for mortality in hemodialysis (HD) patients. SOD, butyrylcholinesterase, and malondialdehyde were estimated spectrophotometrically and the other parameters by standard procedures. High-sensitive C-reactive protein was assayed by a sandwich ELISA method. sUA among survivors (112.1 +/- A 13.82 mu mol/L) was significantly lower than in deceased (160.8 +/- A 16.81 mu mol/L, p  lt  0.001), while SOD was higher in survivors (31.8 +/- A 6.61 kU/L) than among deceased (20.2 +/- A 3.03, p  lt  0.05). Kaplan-Meier survival curves showed the greatest mortality risk in the highest tertile of basal sUA concentration (a parts per thousand yen127.11 mu mol/L, p  lt  0.001), and for SOD in the lowest tertile (a parts per thousand currency sign23.83 kU/L, p  lt  0.05). Our results suggest that high sUA and low SOD may predict all-cause and cardiovascular mortality in HD patients.
PB  - Springer, Dordrecht
T2  - International Urology and Nephrology
T1  - High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients
VL  - 45
IS  - 4
SP  - 1111
EP  - 1119
DO  - 10.1007/s11255-012-0233-x
ER  - 

@article{
author = "Antunović, Tanja and Stefanović, Aleksandra and Ratković, Marina and Gledović, Branka and Gligorović-Barhanović, Najdana and Bozović, Dragica and Ivanišević, Jasmina and Prostran, Milica and Stojanov, Marina",
year = "2013",
abstract = "We investigated the role of serum uric acid (sUA) and superoxide dismutase (SOD) as predictive factors for mortality in hemodialysis (HD) patients. SOD, butyrylcholinesterase, and malondialdehyde were estimated spectrophotometrically and the other parameters by standard procedures. High-sensitive C-reactive protein was assayed by a sandwich ELISA method. sUA among survivors (112.1 +/- A 13.82 mu mol/L) was significantly lower than in deceased (160.8 +/- A 16.81 mu mol/L, p  lt  0.001), while SOD was higher in survivors (31.8 +/- A 6.61 kU/L) than among deceased (20.2 +/- A 3.03, p  lt  0.05). Kaplan-Meier survival curves showed the greatest mortality risk in the highest tertile of basal sUA concentration (a parts per thousand yen127.11 mu mol/L, p  lt  0.001), and for SOD in the lowest tertile (a parts per thousand currency sign23.83 kU/L, p  lt  0.05). Our results suggest that high sUA and low SOD may predict all-cause and cardiovascular mortality in HD patients.",
publisher = "Springer, Dordrecht",
journal = "International Urology and Nephrology",
title = "High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients",
volume = "45",
number = "4",
pages = "1111-1119",
doi = "10.1007/s11255-012-0233-x"
}

Antunović, T., Stefanović, A., Ratković, M., Gledović, B., Gligorović-Barhanović, N., Bozović, D., Ivanišević, J., Prostran, M.,& Stojanov, M.. (2013). High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients. in International Urology and Nephrology
Springer, Dordrecht., 45(4), 1111-1119.
https://doi.org/10.1007/s11255-012-0233-x

Antunović T, Stefanović A, Ratković M, Gledović B, Gligorović-Barhanović N, Bozović D, Ivanišević J, Prostran M, Stojanov M. High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients. in International Urology and Nephrology. 2013;45(4):1111-1119.
doi:10.1007/s11255-012-0233-x .

Antunović, Tanja, Stefanović, Aleksandra, Ratković, Marina, Gledović, Branka, Gligorović-Barhanović, Najdana, Bozović, Dragica, Ivanišević, Jasmina, Prostran, Milica, Stojanov, Marina, "High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients" in International Urology and Nephrology, 45, no. 4 (2013):1111-1119,
https://doi.org/10.1007/s11255-012-0233-x . .

TY  - JOUR
AU  - Stojanov, Marina
AU  - Stefanović, Aleksandra
AU  - Dzingalasević, Gordana
AU  - Ivanišević, Jasmina
AU  - Miljković, Milica
AU  - Mandić-Radić, Slavka
AU  - Prostran, Milica
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1862
AB  - Objective: The aim of this study was to investigate whether high bilirubin concentration is a protective factor in cardiovascular disease (CAD) and how it correlates with parameters of oxidative stress in young males and females. Methods: The study comprised 628 healthy subjects of both genders, 18-22 years of age. In fasting sera the concentration of total bilirubin (Tbil), parameters of cardiovascular risk and oxidative stress were determined. The results were analyzed by appropriate statistical methods. Results: We found no gender differences in body mass index (BMI), blood pressure and lipid profile between subjects with low and high Tbil level. Men with high Tbil had higher concentrations of albumin and uric acid (p  lt  0.001) and lower of oxLDL ( lt 0.05), while women had higher albumin (p  lt  0.05) and lower TBARS (p  lt 0.05). Significant positive correlation in men was found between Tbil, uric acid and albumin, while for glucose and TSARS this association was negative. In female significant positive correlation was between Tbil, HDL-C, fibrinogen, albumin and uric acid and negative between Tbil and TBARS. The high concentration of Tbil in men was independently associated with uric acid (p  lt  0.05) and oxLDL (p  lt  0.001), while in women it was independently associated with TBARS (p  lt 0.05). After adjustment for traditional lipid parameters the predictive power of high bilirubin in men remained for uric acid (p  lt  0.001) and TBARS in women (p  lt  0.05). Conclusion: These findings jointly support the concept that bilirubin via its antioxidant potential has a protective effect against cardiovascular disease in young male and female.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Total bilirubin in young men and women: Association with risk markers for cardiovascular diseases
VL  - 46
IS  - 15
SP  - 1516
EP  - 1519
DO  - 10.1016/j.clinbiochem.2013.06.020
ER  - 

@article{
author = "Stojanov, Marina and Stefanović, Aleksandra and Dzingalasević, Gordana and Ivanišević, Jasmina and Miljković, Milica and Mandić-Radić, Slavka and Prostran, Milica",
year = "2013",
abstract = "Objective: The aim of this study was to investigate whether high bilirubin concentration is a protective factor in cardiovascular disease (CAD) and how it correlates with parameters of oxidative stress in young males and females. Methods: The study comprised 628 healthy subjects of both genders, 18-22 years of age. In fasting sera the concentration of total bilirubin (Tbil), parameters of cardiovascular risk and oxidative stress were determined. The results were analyzed by appropriate statistical methods. Results: We found no gender differences in body mass index (BMI), blood pressure and lipid profile between subjects with low and high Tbil level. Men with high Tbil had higher concentrations of albumin and uric acid (p  lt  0.001) and lower of oxLDL ( lt 0.05), while women had higher albumin (p  lt  0.05) and lower TBARS (p  lt 0.05). Significant positive correlation in men was found between Tbil, uric acid and albumin, while for glucose and TSARS this association was negative. In female significant positive correlation was between Tbil, HDL-C, fibrinogen, albumin and uric acid and negative between Tbil and TBARS. The high concentration of Tbil in men was independently associated with uric acid (p  lt  0.05) and oxLDL (p  lt  0.001), while in women it was independently associated with TBARS (p  lt 0.05). After adjustment for traditional lipid parameters the predictive power of high bilirubin in men remained for uric acid (p  lt  0.001) and TBARS in women (p  lt  0.05). Conclusion: These findings jointly support the concept that bilirubin via its antioxidant potential has a protective effect against cardiovascular disease in young male and female.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Total bilirubin in young men and women: Association with risk markers for cardiovascular diseases",
volume = "46",
number = "15",
pages = "1516-1519",
doi = "10.1016/j.clinbiochem.2013.06.020"
}

Stojanov, M., Stefanović, A., Dzingalasević, G., Ivanišević, J., Miljković, M., Mandić-Radić, S.,& Prostran, M.. (2013). Total bilirubin in young men and women: Association with risk markers for cardiovascular diseases. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 46(15), 1516-1519.
https://doi.org/10.1016/j.clinbiochem.2013.06.020

Stojanov M, Stefanović A, Dzingalasević G, Ivanišević J, Miljković M, Mandić-Radić S, Prostran M. Total bilirubin in young men and women: Association with risk markers for cardiovascular diseases. in Clinical Biochemistry. 2013;46(15):1516-1519.
doi:10.1016/j.clinbiochem.2013.06.020 .

Stojanov, Marina, Stefanović, Aleksandra, Dzingalasević, Gordana, Ivanišević, Jasmina, Miljković, Milica, Mandić-Radić, Slavka, Prostran, Milica, "Total bilirubin in young men and women: Association with risk markers for cardiovascular diseases" in Clinical Biochemistry, 46, no. 15 (2013):1516-1519,
https://doi.org/10.1016/j.clinbiochem.2013.06.020 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Đorđević, S.
AU  - Marić, A.
AU  - Rakonjac, Zorica
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1720
PB  - Springer, Dordrecht
C3  - International Journal of Clinical Pharmacy
T1  - Application of clinical pharmacokinetics to optimize amikacin dosing regimen in neonates
VL  - 34
IS  - 1
SP  - 149
EP  - 149
DO  - 10.1007/s11096-011-9602-2
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Đorđević, S. and Marić, A. and Rakonjac, Zorica and Prostran, Milica",
year = "2012",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Application of clinical pharmacokinetics to optimize amikacin dosing regimen in neonates",
volume = "34",
number = "1",
pages = "149-149",
doi = "10.1007/s11096-011-9602-2"
}

Vučićević, K., Miljković, B., Đorđević, S., Marić, A., Rakonjac, Z.,& Prostran, M.. (2012). Application of clinical pharmacokinetics to optimize amikacin dosing regimen in neonates. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 34(1), 149-149.
https://doi.org/10.1007/s11096-011-9602-2

Vučićević K, Miljković B, Đorđević S, Marić A, Rakonjac Z, Prostran M. Application of clinical pharmacokinetics to optimize amikacin dosing regimen in neonates. in International Journal of Clinical Pharmacy. 2012;34(1):149-149.
doi:10.1007/s11096-011-9602-2 .

Vučićević, Katarina, Miljković, Branislava, Đorđević, S., Marić, A., Rakonjac, Zorica, Prostran, Milica, "Application of clinical pharmacokinetics to optimize amikacin dosing regimen in neonates" in International Journal of Clinical Pharmacy, 34, no. 1 (2012):149-149,
https://doi.org/10.1007/s11096-011-9602-2 . .

TY  - JOUR
AU  - Kocić, Ivana
AU  - Homšek, Irena
AU  - Dacević, Mirjana
AU  - Cvijić, Sandra
AU  - Parojčić, Jelena
AU  - Vučićević, Katarina
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1704
AB  - The aim of this case study was to develop a drug-specific absorption model for levothyroxine (LT4) using mechanistic gastrointestinal simulation technology (GIST) implemented in the GastroPlus (TM) software package. The required input parameters were determined experimentally, in silico predicted and/or taken from the literature. The simulated plasma profile was similar and in a good agreement with the data observed in the in vivo bioequivalence study, indicating that the GIST model gave an accurate prediction of LT4 oral absorption. Additionally, plasma concentrationtime profiles were simulated based on a set of experimental and virtual in vitro dissolution data in order to estimate the influence of different in vitro drug dissolution kinetics on the simulated plasma profiles and to identify biorelevant dissolution specification for LT4 immediate-release (IR) tablets. A set of experimental and virtual in vitro data was also used for correlation purposes. In vitroin vivo correlation model based on the convolution approach was applied in order to assess the relationship between the in vitro and in vivo data. The obtained results suggest that dissolution specification of more than 85% LT4 dissolved in 60 min might be considered as biorelevant dissolution specification criteria for LT4 IR tablets. Copyright
PB  - Wiley-Blackwell, Malden
T2  - Biopharmaceutics & Drug Disposition
T1  - A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets
VL  - 33
IS  - 3
SP  - 146
EP  - 159
DO  - 10.1002/bdd.1780
ER  - 

@article{
author = "Kocić, Ivana and Homšek, Irena and Dacević, Mirjana and Cvijić, Sandra and Parojčić, Jelena and Vučićević, Katarina and Prostran, Milica and Miljković, Branislava",
year = "2012",
abstract = "The aim of this case study was to develop a drug-specific absorption model for levothyroxine (LT4) using mechanistic gastrointestinal simulation technology (GIST) implemented in the GastroPlus (TM) software package. The required input parameters were determined experimentally, in silico predicted and/or taken from the literature. The simulated plasma profile was similar and in a good agreement with the data observed in the in vivo bioequivalence study, indicating that the GIST model gave an accurate prediction of LT4 oral absorption. Additionally, plasma concentrationtime profiles were simulated based on a set of experimental and virtual in vitro dissolution data in order to estimate the influence of different in vitro drug dissolution kinetics on the simulated plasma profiles and to identify biorelevant dissolution specification for LT4 immediate-release (IR) tablets. A set of experimental and virtual in vitro data was also used for correlation purposes. In vitroin vivo correlation model based on the convolution approach was applied in order to assess the relationship between the in vitro and in vivo data. The obtained results suggest that dissolution specification of more than 85% LT4 dissolved in 60 min might be considered as biorelevant dissolution specification criteria for LT4 IR tablets. Copyright",
publisher = "Wiley-Blackwell, Malden",
journal = "Biopharmaceutics & Drug Disposition",
title = "A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets",
volume = "33",
number = "3",
pages = "146-159",
doi = "10.1002/bdd.1780"
}

Kocić, I., Homšek, I., Dacević, M., Cvijić, S., Parojčić, J., Vučićević, K., Prostran, M.,& Miljković, B.. (2012). A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets. in Biopharmaceutics & Drug Disposition
Wiley-Blackwell, Malden., 33(3), 146-159.
https://doi.org/10.1002/bdd.1780

Kocić I, Homšek I, Dacević M, Cvijić S, Parojčić J, Vučićević K, Prostran M, Miljković B. A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets. in Biopharmaceutics & Drug Disposition. 2012;33(3):146-159.
doi:10.1002/bdd.1780 .

Kocić, Ivana, Homšek, Irena, Dacević, Mirjana, Cvijić, Sandra, Parojčić, Jelena, Vučićević, Katarina, Prostran, Milica, Miljković, Branislava, "A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets" in Biopharmaceutics & Drug Disposition, 33, no. 3 (2012):146-159,
https://doi.org/10.1002/bdd.1780 . .